Update on infantile hemangioma
The International Society for the Study of Vascular Anomalies classifies vascular anomalies into vascular tumors and vascular malformations. Vascular tumors are neoplasms of endothelial cells, among which infantile hemangiomas (IHs) are the most common, occurring in 5%–10% of infants. Glucose transp...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Pediatric Society
2021-11-01
|
| Series: | Clinical and Experimental Pediatrics |
| Subjects: | |
| Online Access: | http://www.e-cep.org/upload/pdf/cep-2020-02061.pdf |
| _version_ | 1819024003610705920 |
|---|---|
| author | Hye Lim Jung |
| author_facet | Hye Lim Jung |
| author_sort | Hye Lim Jung |
| collection | DOAJ |
| description | The International Society for the Study of Vascular Anomalies classifies vascular anomalies into vascular tumors and vascular malformations. Vascular tumors are neoplasms of endothelial cells, among which infantile hemangiomas (IHs) are the most common, occurring in 5%–10% of infants. Glucose transporter-1 protein expression in IHs differs from that of other vascular tumors or vascular malformations. IHs are not present at birth but are usually diagnosed at 1 week to 1 month of age, rapidly proliferate between 1 and 3 months of age, mostly complete proliferation by 5 months of age, and then slowly involute to the adipose or fibrous tissue. Approximately 10% of IH cases require early treatment. The 2019 American Academy of Pediatrics clinical practice guideline for the management of IHs recommends that primary care clinicians frequently monitor infants with IHs, educate the parents about the clinical course, and refer infants with high-risk IH to IH specialists ideally at 1 month of age. High-risk IHs include those with life-threatening complications, functional impairment, ulceration, associated structural anomalies, or disfigurement. In Korea, IHs are usually treated by pediatric hematology-oncologists with the cooperation of pediatric cardiologists, radiologists, dermatologists, and plastic surgeons. Oral propranolol, a nonselective beta-adrenergic antagonist, is the first-line treatment for IHs at a dosage of 2–3 mg/kg/day divided into 2 daily doses maintained for at least 6 months and often continuing until 12 months of age. Topical timolol maleate solution, a topical nonselective beta-blocker, may be used for small superficial type IHs at a dosage of 1–2 drops of 0.5% gel-forming ophthalmic solution applied twice daily. Pulse-dye laser therapy or surgery is useful for the treatment of residual skin changes after IH involution. |
| first_indexed | 2024-12-21T04:47:53Z |
| format | Article |
| id | doaj.art-ec931906df014331ad0ce64416368e8a |
| institution | Directory Open Access Journal |
| issn | 2713-4148 |
| language | English |
| last_indexed | 2024-12-21T04:47:53Z |
| publishDate | 2021-11-01 |
| publisher | The Korean Pediatric Society |
| record_format | Article |
| series | Clinical and Experimental Pediatrics |
| spelling | doaj.art-ec931906df014331ad0ce64416368e8a2022-12-21T19:15:31ZengThe Korean Pediatric SocietyClinical and Experimental Pediatrics2713-41482021-11-01641155957210.3345/cep.2020.0206120125555443Update on infantile hemangiomaHye Lim Jung0 Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, KoreaThe International Society for the Study of Vascular Anomalies classifies vascular anomalies into vascular tumors and vascular malformations. Vascular tumors are neoplasms of endothelial cells, among which infantile hemangiomas (IHs) are the most common, occurring in 5%–10% of infants. Glucose transporter-1 protein expression in IHs differs from that of other vascular tumors or vascular malformations. IHs are not present at birth but are usually diagnosed at 1 week to 1 month of age, rapidly proliferate between 1 and 3 months of age, mostly complete proliferation by 5 months of age, and then slowly involute to the adipose or fibrous tissue. Approximately 10% of IH cases require early treatment. The 2019 American Academy of Pediatrics clinical practice guideline for the management of IHs recommends that primary care clinicians frequently monitor infants with IHs, educate the parents about the clinical course, and refer infants with high-risk IH to IH specialists ideally at 1 month of age. High-risk IHs include those with life-threatening complications, functional impairment, ulceration, associated structural anomalies, or disfigurement. In Korea, IHs are usually treated by pediatric hematology-oncologists with the cooperation of pediatric cardiologists, radiologists, dermatologists, and plastic surgeons. Oral propranolol, a nonselective beta-adrenergic antagonist, is the first-line treatment for IHs at a dosage of 2–3 mg/kg/day divided into 2 daily doses maintained for at least 6 months and often continuing until 12 months of age. Topical timolol maleate solution, a topical nonselective beta-blocker, may be used for small superficial type IHs at a dosage of 1–2 drops of 0.5% gel-forming ophthalmic solution applied twice daily. Pulse-dye laser therapy or surgery is useful for the treatment of residual skin changes after IH involution.http://www.e-cep.org/upload/pdf/cep-2020-02061.pdfhemangiomapropranololvascular diseasevascular malformation |
| spellingShingle | Hye Lim Jung Update on infantile hemangioma Clinical and Experimental Pediatrics hemangioma propranolol vascular disease vascular malformation |
| title | Update on infantile hemangioma |
| title_full | Update on infantile hemangioma |
| title_fullStr | Update on infantile hemangioma |
| title_full_unstemmed | Update on infantile hemangioma |
| title_short | Update on infantile hemangioma |
| title_sort | update on infantile hemangioma |
| topic | hemangioma propranolol vascular disease vascular malformation |
| url | http://www.e-cep.org/upload/pdf/cep-2020-02061.pdf |
| work_keys_str_mv | AT hyelimjung updateoninfantilehemangioma |